Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties (Q37761376)

22 August 2017

1 reference

title

Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties (English)

1 reference

22 August 2017

1 reference

1 reference

Sylvia Deppe

1

1 reference

22 August 2017

Rainer H Böger

series ordinal

2

1 reference

22 August 2017

Johanna Weiss

series ordinal

3

1 reference

22 August 2017

Ralf A Benndorf

series ordinal

4

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

Expert Opinion on Drug Metabolism & Toxicology

22 August 2017

1 reference

22 August 2017

6

1 reference

22 August 2017

863-871

1 reference

22 August 2017

7

1 reference

Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study

22 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Chronic renal failure: pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Role of hypertension in atherosclerosis and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Pleiotropic effects of telmisartan: still more to come?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Telmisartan: a review of its use in the management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Telmisartan improves endothelial function in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Gender effects in pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Pharmacokinetics and dosage adjustment in patients with renal dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Telmisartan pharmacokinetics in Japanese renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

No effect of MDR1 C3435T polymorphism on oral pharmacokinetics of telmisartan in 19 healthy Chinese male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Global burden of hypertension: analysis of worldwide data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension--a randomised ABPM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Blood pressure- and pulse pressure-lowering effects, trough:peak ratio and smoothness index of telmisartan compared with lisinopril.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Angiotensin-converting-enzyme inhibition in stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Safety of telmisartan in patients with arterial hypertension : an open-label observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Rapid Identification of P-glycoprotein Substrates and Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.494597

10.1517/17425255.2010.494597

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference